Summary
Final guidance detailing risk‑based Computer Software Assurance for production and quality system software, clarifying documentation expectations, testing approaches, and supplier controls used in medical device manufacturing and quality systems.
Healthcare Implications
Device makers, including AI‑enabled products, should revise validation plans to focus on intended use and risk, streamline evidence, and align Quality Management System procedures and supplier oversight to U.S. Food and Drug Administration expectations.